WO2001083747A3 - Proteines a prions et leurs utilisations - Google Patents

Proteines a prions et leurs utilisations Download PDF

Info

Publication number
WO2001083747A3
WO2001083747A3 PCT/FR2001/001336 FR0101336W WO0183747A3 WO 2001083747 A3 WO2001083747 A3 WO 2001083747A3 FR 0101336 W FR0101336 W FR 0101336W WO 0183747 A3 WO0183747 A3 WO 0183747A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
prion proteins
dna
animal
human
Prior art date
Application number
PCT/FR2001/001336
Other languages
English (en)
Other versions
WO2001083747A2 (fr
Inventor
Pascal Leblanc
Jean-Luc Darlix
Caroline Gabus-Darlix
Original Assignee
Inst Nat Sante Rech Med
Pascal Leblanc
Darlix Jean Luc
Gabus Darlix Caroline
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pascal Leblanc, Darlix Jean Luc, Gabus Darlix Caroline filed Critical Inst Nat Sante Rech Med
Priority to AU2001256454A priority Critical patent/AU2001256454A1/en
Publication of WO2001083747A2 publication Critical patent/WO2001083747A2/fr
Publication of WO2001083747A3 publication Critical patent/WO2001083747A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation

Abstract

La présente invention est relative à des protéines à prion PrP?c ou PrPsc¿, humaines ou animales isolées qui sont capables de se fixer à de l'ADN ou à de l'ARN, en particulier à de l'ADN ou à de l'ARN viral et de préférence à de l'ADN ou à de l'ARN de rétrovirus humains ou animaux, et est relative aux applications biologiques de ces produits.
PCT/FR2001/001336 2000-04-28 2001-04-30 Proteines a prions et leurs utilisations WO2001083747A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001256454A AU2001256454A1 (en) 2000-04-28 2001-04-30 Prion proteins and their uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0005535A FR2808278A1 (fr) 2000-04-28 2000-04-28 Proteines a prions et leurs utilisations
FR00/05535 2000-04-28

Publications (2)

Publication Number Publication Date
WO2001083747A2 WO2001083747A2 (fr) 2001-11-08
WO2001083747A3 true WO2001083747A3 (fr) 2002-02-28

Family

ID=8849762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/001336 WO2001083747A2 (fr) 2000-04-28 2001-04-30 Proteines a prions et leurs utilisations

Country Status (3)

Country Link
AU (1) AU2001256454A1 (fr)
FR (1) FR2808278A1 (fr)
WO (1) WO2001083747A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2267496C2 (ru) * 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221669A (en) * 1991-04-19 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions containing α-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections
WO1997015685A1 (fr) * 1995-10-26 1997-05-01 Winnacker Ernst Ludwig MOLECULES D'ACIDE NUCLEIQUE CAPABLES DE DISTINGUER LES ISOFORMES PrP?C ET PrPSc¿ DE PROTEINES A PRIONS ET PROCEDES DE PRODUCTION DE CES MOLECULES
EP0861900A1 (fr) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Détection immunologique de prions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221669A (en) * 1991-04-19 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions containing α-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections
WO1997015685A1 (fr) * 1995-10-26 1997-05-01 Winnacker Ernst Ludwig MOLECULES D'ACIDE NUCLEIQUE CAPABLES DE DISTINGUER LES ISOFORMES PrP?C ET PrPSc¿ DE PROTEINES A PRIONS ET PROCEDES DE PRODUCTION DE CES MOLECULES
EP0861900A1 (fr) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Détection immunologique de prions

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AKOWITZ ALFRED ET AL: "Endogenous viral complexes with long RNA cosediment with the agent of Creutzfeldt-Jakob disease.", NUCLEIC ACIDS RESEARCH, vol. 22, no. 6, 1994, pages 1101 - 1107, XP002182162, ISSN: 0305-1048 *
FLECHSIG E ET AL: "Expression of PrP in PrP-less mice using an adenovirus vector.", EXPERIENTIA (BASEL), vol. 52, no. ABSTR., 1996, 28th Annual Meeting of the Swiss Societies for Experimental Biology;Zuerich-Irchel, Switzerland; March 27-29, 1996, pages A45, XP002182163, ISSN: 0014-4754 *
GABUS CAROLINE ET AL: "The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein.", JOURNAL OF MOLECULAR BIOLOGY, vol. 307, no. 4, 6 April 2001 (2001-04-06), pages 1011 - 1021, XP002182165, ISSN: 0022-2836 *
GABUS CAROLINE ET AL: "The prion protein has RNA binding and chaperoning properties characteristic of nucleocapsid protein NCp7 of HIV-1.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 22, 1 June 2001 (2001-06-01), pages 19301 - 19309, XP002182166, ISSN: 0021-9258 *
MANUELIDIS L ET AL: "VIRAL PARTICLES ARE REQUIRED FOR INFECTION IN NEURODEGENERATIVE CREUTZFELDT-JAKOB DISEASE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, May 1995 (1995-05-01), pages 5124 - 5128, XP002912148, ISSN: 0027-8424 *
MURDOCH G H ET AL: "POTENTIAL RETROVIRAL RNA IN CREUTZFELDT-JAKOB DISEASE", JOURNAL OF VIROLOGY, vol. 64, no. 4, 1990, pages 1477 - 1486, XP001031276, ISSN: 0022-538X *
NANDI P K ET AL: "Murine recombinant prion protein induces ordered aggregation of linear nucleic acids to condensed globular structures.", ARCHIVES OF VIROLOGY, vol. 146, no. 2, 14 March 2001 (2001-03-14), pages 327 - 345, XP002182164, ISSN: 0304-8608 *
NIEVA JOSE L ET AL: "Similarities of prion protein to fusion/entry proteins of HIV and ebola: Membrane interactions of its putative fusion domain.", BIOPHYSICAL JOURNAL, vol. 78, no. 1 Part 2, January 2000 (2000-01-01), 44th Annual Meeting of the Biophysical Society.;New Orleans, Louisiana, USA; February 12-16, 2000, pages 412A, XP001031295, ISSN: 0006-3495 *
SCOTT M R ET AL: "CHIMERIC PRION PROTEIN EXPRESSION IN CULTURED CELLS AND TRANSGENIC MICE", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 1, no. 8, 1 August 1992 (1992-08-01), pages 986 - 997, XP000675245, ISSN: 0961-8368 *

Also Published As

Publication number Publication date
FR2808278A1 (fr) 2001-11-02
WO2001083747A2 (fr) 2001-11-08
AU2001256454A1 (en) 2001-11-12

Similar Documents

Publication Publication Date Title
WO1999038972A8 (fr) Genes humains et produits ii d'expression genique
WO2002014500A3 (fr) Genes humains et produits d'expression genique
WO1999058675A3 (fr) Genes humains et produits d'expression genique v
WO1999033982A3 (fr) Genes humains et produits d'expression genique i
WO2001066753A3 (fr) Nouveaux genes humains et leurs produits d'expression
WO2002040668A3 (fr) Proteines et sequences d'adn sous-jacentes a ces proteines, utilisees pour traiter les inflammations
WO2006047728A3 (fr) Genes bmp et proteines de fusion
WO2005026205A3 (fr) Produits geniques exprimes de maniere differentielle dans des tumeurs et leur utilisation
WO2003016551A3 (fr) Proteine de liaison a l'acide salicylique codant des acides nucleiques, proteine de liaison a l'acide salicylique 2 (sabp2) et methodes d'utilisation associees
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
WO2001045738A3 (fr) Utilisation de proteines de choc thermique
WO2001083747A3 (fr) Proteines a prions et leurs utilisations
EP1133997A3 (fr) Traitement de maladies immunes par l'inteferon beta
WO2000018916A3 (fr) Genes humains et produits d'expression genique
GB2349150B (en) Expression of DNA or proteins in C. Elegans
WO2001072781A3 (fr) Genes humains et produits d'expression genique xvi
WO2005023979A3 (fr) Molecules d'acide nucleique de s. mansoni isolees et utilisations associees
AU2001290872A1 (en) Isolated human kinase proteins, nucleic acid molecules and uses thereof
WO2000042063A3 (fr) Peptides pour l'inhibition des proteines noyaux du virus de l'hepatite b
EP1383871A4 (fr) Proteines enzymatiques humaines isolees, molecules d'acides nucleiques codant pour ces proteines, et leurs utilisations
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
WO2001049839A3 (fr) Procede d'expression genique et son utilisation
EP1383877A4 (fr) Proteines enzymatiques humaines isolees, molecules d'acides nucleiques codant des proteines enzymatiques humaines, et utilisations associees
EP1383876A4 (fr) Proteines enzymatiques humaines isolees, molecules d'acides nucleiques codant des proteines enzymatiques humaines et leurs utilisations
AU2002228599A1 (en) Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP